NarrativeA novel self-assembly process, developed at the University of Strathclyde was shown to provide a step-change for stabilising proteins as dry powders. The spin-out company, XstalBio, was created in 2004 and licensed the patented technology with the aim of developing it for delivery and formulation of therapeutic biomolecules and vaccines. Over the period 2008-2012, eight leading international pharmaceutical and animal health companies paid XstalBio over £2.2M for access to its IP portfolio and to undertake evaluation studies with candidate biomedicines and vaccines. XstalBio employed 8 highly skilled research scientists over this period and 4 further patent families were generated. Boehringer Ingelheim licensed the technology for application to its therapeutic biomolecules and in collaboration with XstalBio built a dedicated €5M pilot plant for manufacture of inhalable dry powders.
|Category of impact||Economic and commerce, Health and welfare - new products, guidelines and services|
- REF2014 impact case study
Documents & Links
Research output: Contribution to journal › Article › peer-review
Ex-vivo perfusion bioassay: an excellent technique to measure the bioactivity of inhalable insulin coated microcrystals
Research output: Contribution to conference › Poster